OTCMKTS:HCYTD H-CYTE (HCYTD) Stock Forecast, Price & News $2.02 -1.98 (-49.50%) (As of 07/11/2022) Add Compare Share Share Today's Range$2.02▼$2.7750-Day Range$2.02▼$2.0252-Week Range$2.02▼$77.00Volume400 shsAverage Volume103 shsMarket Capitalization$521,160.00P/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsShort InterestProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest About H-CYTE (OTCMKTS:HCYTD) StockH-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.Read More Receive HCYTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter. Email Address HCYTD Stock News HeadlinesJune 7, 2023 | americanbankingnews.comH-CYTE (OTCMKTS:HCYTD) versus BrainsWay (NASDAQ:BWAY) Critical SurveyMay 12, 2023 | marketwatch.com10-K: H-CYTE, INC.June 10, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.April 14, 2023 | americanbankingnews.comAvinger (NASDAQ:AVGR) versus H-CYTE (OTCMKTS:HCYTD) Financial SurveyApril 1, 2023 | americanbankingnews.comHead to Head Comparison: Arch Therapeutics (OTCMKTS:ARTH) and H-CYTE (OTCMKTS:HCYTD)March 24, 2023 | seekingalpha.comHCYT H-CYTE, Inc.September 8, 2022 | finance.yahoo.comH-CYTE Completes Acquisition of JantibodyJuly 23, 2022 | apnews.comH-CYTE to Expect the Completed Acquisition of Jantibody Within 30 DaysJune 10, 2023 | Stansberry Research (Ad)The gold catalyst we've waited forBecause even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.June 13, 2022 | finance.yahoo.comH-CYTE Announces 1-for-1,000 Reverse Stock SplitMarch 6, 2022 | yahoo.comShould You Refrigerate Peanut Butter?March 6, 2022 | yahoo.comNetflix’s new superhero show might be the weirdest thing you ever watchMarch 4, 2022 | finance.yahoo.comH-CYTE Announces Proceeds of $1.05 Million from Warrant ExerciseFebruary 7, 2022 | nasdaq.comH-CYTE Inc (HCYT)January 11, 2022 | seekingalpha.comH-CYTE signs letter of intent to acquire Catheter PrecisionJanuary 11, 2022 | finance.yahoo.comH-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.December 6, 2021 | finance.yahoo.comH-CYTE Names Michael Yurkowsky Chief Executive OfficerSeptember 9, 2021 | au.finance.yahoo.comItalian court seeks opinion on Berlusconi's health due to trial delaysSeptember 8, 2021 | finance.yahoo.comH-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory HealthJuly 7, 2021 | ca.finance.yahoo.comJefferson Lines takes proactive steps toward crisis management with TSA I-STEP trainingJuly 7, 2021 | in.finance.yahoo.comScanfil plc: Managers' transactions – JokitaloJuly 6, 2021 | finance.yahoo.comH-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung HealthJuly 1, 2021 | in.finance.yahoo.comConstellium supplies advanced aluminium solutions for the electric Audi e-tron GTJuly 1, 2021 | au.finance.yahoo.comNetNumber Named as One of the “10 Most Disruptive Companies of 2021” by Exceleon MagazineJune 29, 2021 | finance.yahoo.comH-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung HealthOctober 4, 2020 | msn.comNew Providence CEO: 'We have a responsibility and accountability to the community'September 29, 2020 | feeds.benzinga.comRobert Greif named Chief Executive Officer of H-CYTESee More Headlines HCYTD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HCYTD Company Calendar Today6/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical & Medical Instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:HCYTD CUSIPN/A CIK1591165 Webwww.hcyte.com Phone(844) 633-6839FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,800,000.00 Net Margins-450.40% Pretax Margin-450.40% Return on EquityN/A Return on Assets-777.68% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$1.61 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($31.45) per share Price / Book-0.06Miscellaneous Outstanding Shares258,000Free Float244,000Market Cap$521,160.00 OptionableNot Optionable Beta1.12 Key ExecutivesMr. Michael W. Yurkowsky (Age 50)CEO & Director Comp: $180kMr. Jeremy Daniel (Age 46)Chief Financial Officer Comp: $200kDr. Tanya Rhodes Ph.D. (Age 61)Chief Scientific Officer Comp: $252kMr. Jeffery Wright CPA (Age 39)CPA, Controller & Principal Accounting Officer Key CompetitorsRenovaCareOTCMKTS:RCARG Medical InnovationsNASDAQ:GMVDRegenicinOTCMKTS:RGINQuantRx BiomedicalOTCMKTS:QTXBHypertension DiagnosticsOTCMKTS:HDIIView All Competitors HCYTD Stock - Frequently Asked Questions How have HCYTD shares performed in 2023? H-CYTE's stock was trading at $2.02 on January 1st, 2023. Since then, HCYTD shares have increased by 0.0% and is now trading at $2.02. View the best growth stocks for 2023 here. What is H-CYTE's stock symbol? H-CYTE trades on the OTCMKTS under the ticker symbol "HCYTD." How do I buy shares of H-CYTE? Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is H-CYTE's stock price today? One share of HCYTD stock can currently be purchased for approximately $2.02. How much money does H-CYTE make? H-CYTE (OTCMKTS:HCYTD) has a market capitalization of $521,160.00 and generates $1.61 million in revenue each year. How can I contact H-CYTE? H-CYTE's mailing address is 201 E Kennedy Blvd Suite 700, Tampa FL, 33602. The official website for the company is www.hcyte.com. The company can be reached via phone at (844) 633-6839 or via email at jassad@hcyte.com. This page (OTCMKTS:HCYTD) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H-CYTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.